Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., Byrne, J. L., de Lavallade, H., O'Brien, S. G., Coffey, T., Foroni, L., & Copland, M. (2017). A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study. Lancet Haematology, 4(7), e310-e316. https://doi.org/10.1016/S2352-3026%2817%2930066-2